Neha Gupta
2 min read
In This Article:
Ascendis Pharma A/S (NASDAQ:ASND) is one of the best 52-week high stocks to buy, according to analysts. On June 9, BofA analyst Tazeen Ahmad reiterated a 'Buy' rating on the stock and raised the price target to $216 from $201.
A biopharmaceutical scientist wearing a lab coat, examining a microscope of cells.
The adjustment follows the company delivering positive interim results from the Phase 2 COACH trial. The trial sought to ascertain the effectiveness of a combination treatment QW TransCon CNP and QW TransCon HGH in children with Achondroplasia (ACH). Trial results indicated significant annualized growth velocity benefits with the combination treatment.
According to the analyst, the trial results are favorable and likely to strengthen the company's prospects of capturing market share once the treatment enters the market. Following the positive trial results, Ascendis plans to release 52-week data from the COACH trial in the fourth quarter.
Likewise, the US Food and Drug Administration (FDA) has accepted the company's New Drug Application for TransCon, its candidate drug for treating achondroplasia.
Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company that develops and commercializes new therapies for unmet medical needs, particularly in endocrinology and oncology. It leverages a proprietary TransCon technology platform to create innovative and potentially best-in-class therapies.
While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Most Popular AI Stocks to Avoid Now and Billionaire David E. Shaw’s 10 Small-Cap Stock Picks with Huge Upside Potential.
Disclosure: None.
